Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,454 signal articles · 231 in last 24h · 132,887 total before filter · latest 53m ago
231last 24h
1166last 7d
203● bullish (7d)
123● bearish (7d)
208publishers
AllMacro281Earnings427M&A72Regulatory22Product10Analyst20
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Eli Lilly (LLY) Stock May Be 30% Undervalued Despite Fresh FDA Approval
Simply Wall St.2d agoneutral
Eli Lilly (LLY) Stock May Be 30% Undervalued Despite Fresh FDA Approval

Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside, while market based multiples look closer to fair. Eli Lilly has returned 373.6% over five years, which puts a lot of optimism into the share price and raises the bar for what counts as good value today. The expanded use of drugs like Mounjaro and Zepbound in metabolic and cardiovascular care...

New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst
Insider Monkey6d agoneutral
New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]

KKR Hit With $250 Million Penalty Over Antitrust Violations
Benzinga Private Markets6d agoneutral
KKR Hit With $250 Million Penalty Over Antitrust Violations

KKR & Co. (NYSE:KKR) is set to pay a $250 million civil penalty after the private equity firm allegedly violated the Hart-Cottrell-Rodino Act by withholding and altering documents and failing to make required filings. The HSR Act requires M&A parties...

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
Benzinga7d agoneutral
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
Simply Wall St.13d agoneutral
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...

Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval Lands
Simply Wall St.18d agoneutral
Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval Lands

Bristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation work using a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples both currently point to the shares trading at a discount to that estimate. For investors, that combination of strong recent returns and a still supportive valuation framework raises the question of how much margin of safety may remain in the current price. The 38.1% one year return shows that sentiment toward...

Loss of Market Share in U.S. Antitrust Consulting Pressures FTI Consulting’s (FCN) Top-Line Performance
Insider Monkey20d agoneutral
Loss of Market Share in U.S. Antitrust Consulting Pressures FTI Consulting’s (FCN) Top-Line Performance

Sycamore Capital Management, a franchise of Victory Capital Management, released its Q2 2026 investor letter for “Sycamore Mid Cap Value Equity Strategy”. A copy of the letter can be downloaded here. Sycamore Capital’s Mid Cap Value investment team focuses on a bottom-up approach to identify undervalued businesses with growth potential. In Q2 2026, the strategy […]

Investing.com21d agoneutral
Paramount puts CNN sale on table to settle 12-state antitrust suit

Makan Delrahim made the disclosure at Politico’s California Agenda conference, according to Reuters, signaling that Paramount is willing to go beyond internal safeguards to salvage a deal that has become one of the most politically charged media mergers in years. Warner Bros. Discovery is the publicly traded parent of CNN (NASDAQ: WBD), and the merger’s fate directly determines whether Ellison’s Paramount consolidates control over both CBS News and the cable network.

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?
Insider Monkey23d agoneutral
Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review
The Wall Street Journal28d agoneutral
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review

The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.

Is Amazon.com (AMZN) A Bargain Following Its Latest Lawsuit And AI Fueled Rally?
Simply Wall St.29d agoneutral
Is Amazon.com (AMZN) A Bargain Following Its Latest Lawsuit And AI Fueled Rally?

Amazon.com (AMZN) stock is in focus after a consumer lawsuit filed on July 31, 2026, alleged the retailer sold Orgain protein powder containing harmful levels of heavy metals and misrepresented the products’ safety and quality attributes. See our latest analysis for Amazon.com. After the latest lawsuit headlines, Amazon.com’s recent share price moves still reflect strong momentum, with a 7 day share price return of 23.03% and a 1 year total shareholder return of 32.87%, which points to...